AC Immune SA ACIU 深 沪
已收盘 07-02 16:00:00 美东时间
2.51
+0.130
+5.46%
华盛通- 最 高2.52
- 今 开2.37
- 成交量 36.49万股
- 最 低 2.35
- 昨 收 2.38
- 总市值 2.55亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 2.00
- 委 比 5.58%
- 总股本 1.02亿
- 历史最高 17.40
- 量 比 0.99
- 振 幅 7.14%
- 历史最低 1.4299
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多阿尔茨海默病概念股日内下跌 AC Immune跌8.94% 礼来跌2.62% 渤健跌1.37%
阿尔茨海默病概念股在盘中交易中走低，相关个股跌幅如下： AC免疫公司下跌8.94% 礼来公司下跌2.62% 渤健公司下滑1.37% 译文内容由第三方软件翻译...
06-30 22:46
AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three Cohorts
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer’s disease (AD) in the Phase 1b/2 ABATE trial fol...
06-30 19:14
AC Immune Gets $4M Grant for Parkinson's Trial Extension
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of t...
06-11 19:05
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune has received a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson’s disease. The grant will support a two-year extension to assess long-term safety and efficacy, with final Part 1 data expected in H2 2026. The Goradia Foundation aims to advance knowledge of PD and bring ACI-7104 to ear...
06-11 11:00
AC Immune Presents New Preliminary Data From Phase 1 Trial Of TDP-43 Positron Emission Tomography Tracer ACI-19626 Showing Increased Uptake In Brains Of Patients With Amyotrophic Lateral Sclerosis
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSPresentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic
05-22 19:08
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune presented new Phase 1 data showing higher uptake of its TDP-43 PET tracer ACI-19626 in the brains of ALS patients compared to healthy controls. The tracer detected TDP-43 pathology in key brain regions, with previous data also showing its ability to detect TDP-43 in genetic frontotemporal dementia (FTD). ACI-19626 demonstrated good safety, tolerability, and a suitable pharmacokinetic profile for brain imaging. The ongoing Phase 1 trial ...
05-22 11:00
AC Immune CEO Andrea Pfeifer to retire after 23 years
AC Immune (ACIU) on Tuesday said co-founder and CEO Andrea Pfeifer will retire at the company’s upcoming annual general meeting after leading the neurodegenerative disease drug developer for 23 years....
05-12 20:15
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune announced that Dr. Andrea Pfeifer, its co-founder and CEO, will retire at the upcoming AGM after 23 years of service. Dr. Martin Zügel, the Board Chair, will serve as interim CEO while a permanent successor is sought. Dr. Pfeifer will continue as an advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board. The company is well-positioned to create value through its pipeline and partnerships, with a strong finan...
05-12 11:00
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
